MWM
AXSM icon

Meridian Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

Meridian Wealth Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.72M Buy
22,024
+300
+1% +$51.8K 0.13% 147
2025
Q4 		$3.97M Sell
21,724
-400
-2% -$55.8K 0.14% 139
2025
Q3 		$2.69M Buy
22,124
+103
+0.5% +$11.6K 0.1% 176
2025
Q2 		$2.3M Buy
22,021
+1,000
+5% +$106K 0.1% 183
2025
Q1 		$2.45M Sell
21,021
-150
-0.7% -$17.1K 0.12% 168
2024
Q4 		$1.79M Buy
21,171
+150
+0.7% +$13.8K 0.08% 202
2024
Q3 		$1.89M Sell
21,021
-35
-0.2% -$3.06K 0.09% 185
2024
Q2 		$1.7M Buy
+21,056
New +$1.56M 0.2% 88
2024
Q1 		– Sell
-20,498
Closed -$1.63M – 214
2023
Q4 		$1.63M Buy
20,498
+1,275
+7% +$85.2K 0.1% 189
2023
Q3 		$1.34M Buy
19,223
+250
+1% +$18.7K 0.08% 201
2023
Q2 		$1.36M Buy
18,973
+2,500
+15% +$184K 0.11% 160
2023
Q1 		$1.02M Buy
16,473
+1,525
+10% +$100K 0.09% 206
2022
Q4 		$1.15M Buy
14,948
+1,878
+14% +$112K 0.11% 173
2022
Q3 		$583K Buy
13,070
+5,140
+65% +$257K 0.06% 255
2022
Q2 		$304K Buy
+7,930
New +$251K 0.02% 436

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Meridian Wealth Management's AXSM Position: Q1 2026 in Review

Meridian Wealth Management increased its Axsome Therapeutics (AXSM) stake by 1.4% in Q1 2026, buying an estimated $51.8K and bringing the position to 22,024 shares worth $3.72M. The position accounts for 0.13% of the portfolio, ranked #147.

Meridian Wealth Management first reported a position in AXSM in Q2 2022 and has held it in 15 quarters since. The position peaked at $3.97M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Meridian Wealth Management held 22,024 shares of Axsome Therapeutics worth $3.72M as of Q1 2026.
  • Meridian Wealth Management bought 300 Axsome Therapeutics shares in Q1 2026, an estimated $51.8K.
  • Axsome Therapeutics made up 0.13% of Meridian Wealth Management's portfolio in Q1 2026, its #147 holding.
  • Meridian Wealth Management first reported a position in Axsome Therapeutics in Q2 2022 and has held it in 15 quarters since.
  • Meridian Wealth Management's Axsome Therapeutics position peaked at $3.97M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Meridian Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.